Autor(es):
Kissling, Esther ; Hooiveld, Mariëtte ; Martínez-Baz, Iván ; Mazagatos, Clara ; William, Naoma ; Vilcu, Ana-Maria ; Kooijman, Marjolein N. ; Ilić, Maja ; Domegan, Lisa ; Machado, Ausenda ; de Lusignan, Simon ; Lazar, Mihaela ; Meijer, Adam ; Brytting, Mia ; Casado, Itziar ; Larrauri, Amparo ; Murray, Josephine-L.K. ; Behillil, Sylvie ; de Gier, Brechje ; Mlinarić, Ivan ; O’Donnell, Joan ; Rodrigues, Ana Paula ; Tsang, Ruby ; Timnea, Olivia ; de Lange, Marit ; Riess, Maximilian ; Castilla, Jesús ; Pozo, Francisco ; Hamilton, Mark ; Falchi, Alessandra ; Knol, Mirjam J. ; Kurečić Filipović, Sanja ; Dunford, Linda ; Guiomar, Raquel ; Cogdale, Jade ; Cherciu, Carmen ; Jansen, Tessa ; Enkirch, Theresa ; Basile, Luca ; Connell, Jeff ; Gómez, Verónica ; Sandonis Martín, Virginia ; Bacci, Sabrina ; Rose, Angela M.C. ; Pastore Celentano, Lucia ; Valenciano, Marta ; I-MOVE-COVID-19 and ECDC primary care study teams
Data: 2022
Identificador Persistente: http://hdl.handle.net/10400.18/8920
Origem: Repositório Científico do Instituto Nacional de Saúde
Assunto(s): COVID-19; SARS-CoV-2; Delta Variant; Multicentre Study; Test-negative Design; Vaccine Effectiveness; Europe; Vacina; Efetividade; Infecções Respiratórias; Cuidados de Saúde; Europa; I-MOVE
Descrição
Introduction: In July and August 2021, the SARS-CoV-2 Delta variant dominated in Europe. Aim: Using a multicentre test-negative study, we measured COVID-19 vaccine effectiveness (VE) against symptomatic infection. Methods: Individuals with COVID-19 or acute respiratory symptoms at primary care/community level in 10 European countries were tested for SARS-CoV-2. We measured complete primary course overall VE by vaccine brand and by time since vaccination. Results: Overall VE was 74% (95% CI: 69–79), 76% (95% CI: 71–80), 63% (95% CI: 48–75) and 63% (95% CI: 16–83) among those aged 30–44, 45–59, 60–74 and ≥ 75 years, respectively. VE among those aged 30–59 years was 78% (95% CI: 75–81), 66% (95% CI: 58–73), 91% (95% CI: 87–94) and 52% (95% CI: 40–61), for Comirnaty, Vaxzevria, Spikevax and COVID-19 Vaccine Janssen, respectively. VE among people 60 years and older was 67% (95% CI: 52–77), 65% (95% CI: 48–76) and 83% (95% CI: 64–92) for Comirnaty, Vaxzevria and Spikevax, respectively. Comirnaty VE among those aged 30–59 years was 87% (95% CI: 83–89) at 14–29 days and 65% (95% CI: 56–71%) at ≥ 90 days between vaccination and onset of symptoms. Conclusions: VE against symptomatic infection with the SARS-CoV-2 Delta variant varied among brands, ranging from 52% to 91%. While some waning of the vaccine effect may be present (sample size limited this analysis to only Comirnaty), protection was 65% at 90 days or more between vaccination and onset.
